No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)


Rajeev, Surya, Roberts, Carl ORCID: 0000-0003-4275-601X, Brown, Emily, Sprung, Victoria ORCID: 0000-0002-2666-4986, Harrold, Jo ORCID: 0000-0002-0899-4586, Halford, Jason, Stancak, Andrej ORCID: 0000-0003-3323-3305, Boyland, Emma ORCID: 0000-0001-8384-4994, Kemp, Graham ORCID: 0000-0002-8324-9666, Perry, Julie et al (show 4 more authors) (2023) No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE) Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 25 (12). pp. 3621-3631. ISSN 1462-8902, 1463-1326

[thumbnail of ENERGIZE manuscript accepted version.docx] Microsoft Word (OpenXML)
ENERGIZE manuscript accepted version.docx - Author Accepted Manuscript
Download (1MB)

Abstract

Aim: This study assessed the impact of dapagliflozin on food intake, eating behaviour, energy expenditure, magnetic resonance imaging (MRI)-determined brain response to food cues and body composition in patients with type 2 diabetes mellitus (T2D). Materials and Methods: Patients were given dapagliflozin 10 mg once daily in a randomized, double-blind, placebo-controlled trial with short-term (1 week) and long-term (12 weeks) cross-over periods. The primary outcome was the difference in test meal food intake between long-term dapagliflozin and placebo treatment. Secondary outcomes included short-term differences in test meal food intake, short- and long-term differences in appetite and eating rate, energy expenditure and functional MRI brain activity in relation to food images. We determined differences in glycated haemoglobin, weight, liver fat (by 1H magnetic resonance spectroscopy) and subcutaneous/visceral adipose tissue volumes (by MRI). Results: In total, 52 patients (43% were women) were randomized; with the analysis of 49 patients: median age 58 years, weight 99.1 kg, body mass index 35 kg/m2, glycated haemoglobin 49 mmol/mol. Dapagliflozin reduced glycated haemoglobin by 9.7 mmol/mol [95% confidence interval (CI) 3.91-16.27, p =.004], and body weight (−2.84 vs. −0.87 kg) versus placebo. There was no short- or long-term difference in test meal food intake between dapagliflozin and placebo [mean difference 5.7 g (95% CI −127.9 to 139.3, p =.933); 15.8 g (95% CI −147.7 to 116.1, p =.813), respectively] nor in the rate of eating, energy expenditure, appetite, or brain responses to food cues. Liver fat (median reduction −4.7 vs. 1.95%), but not subcutaneous/visceral adipose tissue, decreased significantly with 12 weeks of dapagliflozin. Conclusions: The reduction in body weight and liver fat with dapagliflozin was not associated with compensatory adaptations in food intake or energy expenditure.

Item Type: Article
Uncontrolled Keywords: dapagliflozin, clinical trial, appetite control, SGLT2 inhibitor, energy regulation
Divisions: Faculty of Health & Life Sciences
Faculty of Health & Life Sciences > Inst. Population Health
Depositing User: Symplectic Admin
Date Deposited: 05 Sep 2023 14:24
Last Modified: 22 Jan 2026 21:02
DOI: 10.1111/dom.15257
Related Websites:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3172546
Disclaimer: The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.
Altmetric
CORE (COnnecting REpositories)